News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pfizer Inc. (PFE) Faces Legal Action From Australian Competition Regulator



2/13/2014 7:16:51 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Australia's competition regulator said on Thursday it was taking legal action against the local division of Pfizer Inc over the way it marketed its cholesterol-lowering drug Lipitor to pharmacies. The Australian Competition and Consumer Commision (AC) said Pfizer had, to deter competition, offered pharmacies "significant" discounts and rebates if they stocked at least a year's worth of the drug, which goes by the generic name atorvastatin and is prescribed to over one million Australians. The drug had generated annual sales exceeding A$700 million ($632.35 million) for Pfizer in Australia before the company's patent expired in there in May 2012, the ACCC said.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at BusinessWeek
Read at Market Watch
Read at Wall Street Journal


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES